Form 4: Exelixis Director Mary C. Beckerle Receives RSU Grant

Director Mary C. Beckerle was granted 8,367 restricted stock units as part of the Exelixis, Inc. 2017 Equity Incentive Plan.

Summary

• Director Mary C. Beckerle acquired 8,367 restricted stock units (RSUs) on May 27, 2026.
• The RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan.
• Each RSU represents the economic equivalent of one share of common stock.
• The total beneficial ownership following the transaction is 25,891 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to the Reporting Person's continuous service through the May 27, 2027, vesting date.

Future Outlook

The RSUs are scheduled to vest 100% on May 27, 2027, provided the director maintains continuous service.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the biotechnology sector to ensure alignment between leadership and shareholders.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for mid-to-large cap biotechnology companies.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity incentive grant.

Next Steps

• Vesting of the 8,367 RSUs on May 27, 2027.

Key Dates

Keywords

Exelixis, EXEL, Insider Trading, Form 4, Equity Incentive Plan, Director Compensation